Targeting the Wnt Pathway Fails in OA— In a phase IIa trial of knee osteoarthritis, lorecivivint failed to meet the primary pain endpoint:
https://www.medpagetoday.com/rheumatology/arthritis/86677
May 26, 2020
The Wnt pathway modulator lorecivivint failed to meet the primary endpoint in a phase IIa study for knee osteoarthritis (OA), but showed promise in certain patient subgroups, researchers reported.
On the primary endpoint, which was improvement in pain on the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index, no dose of intra-articular lorecivivint (0.03 mg, 0.07 mg, or 0.23 mg) showed statistically significant differences from placebo at week 13, according to Yusuf Yazici, MD, of NYU Langone Medical Center in New York City, and colleagues. Yazici is also chief medical officer of Samumed, the study sponsor.
However, in a post-hoc exploratory analysis of a subgroup of patients who had unilateral knee pain, patients receiving the 0.07-mg dose had significant improvements at week 52 on WOMAC pain scores, with a between-group difference of -8.73 (95% CI -17.44 to -0.03, P=0.049), and also on function scores, with a between-group difference of -10.26 (95% CI -19.82 to -0.69, P=0.036), they reported online in Arthritis & Rheumatology.
Nonetheless, "the study was negative," commented David T. Felson, MD, of Boston University School of Medicine, who was not involved in the study. "They did some secondary analyses where they tried to find a positive subgroup, but those usually aren't very robust in terms of findings," he said."The results are discouraging," Felson told MedPage Today.
Sorry..oxxa, didn't see your link.
- Forums
- ASX - By Stock
- PAR
- research reports and media
research reports and media, page-1521
-
- There are more pages in this discussion • 2,908 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
21.0¢ |
Change
0.015(7.69%) |
Mkt cap ! $73.55M |
Open | High | Low | Value | Volume |
20.5¢ | 21.0¢ | 20.0¢ | $216.0K | 1.057M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 143324 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.0¢ | 44935 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 138349 | 0.200 |
9 | 191984 | 0.195 |
15 | 199884 | 0.190 |
6 | 161140 | 0.185 |
16 | 784128 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.210 | 44935 | 3 |
0.215 | 132157 | 4 |
0.220 | 82155 | 7 |
0.225 | 31604 | 3 |
0.230 | 33834 | 4 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
EL8
ELEVATE URANIUM LTD
Murray Hill, MD & CEO
Murray Hill
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online